Papp L Roy & Associates increased its position in shares of Mednax Inc. (NYSE:MD) by 12.2% during the second quarter, Holdings Channel reports. The firm owned 11,483 shares of the company’s stock after buying an additional 1,245 shares during the period. Papp L Roy & Associates’ holdings in Mednax were worth $832,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in MD. Aperio Group LLC increased its stake in shares of Mednax by 19.8% in the first quarter. Aperio Group LLC now owns 18,972 shares of the company’s stock valued at $1,226,000 after buying an additional 3,136 shares during the period. Legal & General Group Plc increased its stake in shares of Mednax by 17.4% in the first quarter. Legal & General Group Plc now owns 63,195 shares of the company’s stock valued at $4,085,000 after buying an additional 9,350 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Mednax during the first quarter valued at about $28,536,000. State of Alaska Department of Revenue increased its stake in shares of Mednax by 6.9% in the second quarter. State of Alaska Department of Revenue now owns 9,780 shares of the company’s stock valued at $708,000 after buying an additional 630 shares during the period. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Mednax by 1,821.7% in the second quarter. BNP Paribas Arbitrage SA now owns 39,279 shares of the company’s stock valued at $2,845,000 after buying an additional 37,235 shares during the period. Institutional investors own 97.75% of the company’s stock.
Mednax Inc. (NYSE:MD) traded down 0.18% during midday trading on Tuesday, reaching $65.77. 597,334 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $65.43 and a 200 day moving average price of $68.29. The company has a market cap of $6.06 billion, a price-to-earnings ratio of 18.36 and a beta of 0.54. Mednax Inc. has a 52 week low of $61.40 and a 52 week high of $83.20.
Mednax (NYSE:MD) last announced its quarterly earnings results on Thursday, July 28th. The company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.07 by $0.04. The firm had revenue of $772 million for the quarter, compared to the consensus estimate of $775.68 million. Mednax had a return on equity of 14.88% and a net margin of 11.17%. The company’s revenue for the quarter was up 14.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.90 earnings per share. Analysts anticipate that Mednax Inc. will post $4.14 EPS for the current year.
A number of equities analysts have recently weighed in on MD shares. Citigroup Inc. dropped their price target on shares of Mednax from $76.00 to $72.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 17th. Zacks Investment Research raised shares of Mednax from a “hold” rating to a “buy” rating and set a $80.00 price target on the stock in a research note on Wednesday, June 29th. JPMorgan Chase & Co. dropped their price target on shares of Mednax from $85.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 29th. Jefferies Group dropped their price target on shares of Mednax from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday, August 26th. Finally, Mizuho reaffirmed a “buy” rating and issued a $79.00 price target on shares of Mednax in a research note on Tuesday, September 20th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $76.11.
In other news, Director Md Pascal J. Goldschmidt sold 1,500 shares of Mednax stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $65.01, for a total transaction of $97,515.00. Following the transaction, the director now directly owns 12,755 shares of the company’s stock, valued at $829,202.55. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax Inc. (NYSE:MD).
Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.